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Abstract The synthetic disaccharide precursor of lipid A (406: identical to lipid IVA) was found to reduce its endotoxic activity in mice by an order 
of 105 or more, by replacing the hydroxyl groups with succinyl or acetyl residues. Both the succinylated and acetylated 406 were also found to 
antagonize the endotoxic mitogenicity on murine splenocytes. Previous tudies demonstrated that the succinylated oracetylated synthetic complete 
lipid A preparations retained the whole endotoxic activity [1994, Infect, Immunol. 62, 1705]. The drastic ontrast in all of these results uggests the 
importance of the substituents on the hydroxyl groups of 3-hydroxy fatty acids of non-reducing glucosamine of lipid A for the activity and for 
transformation to the antagonistic structure. 
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1. Introduction 
Lipid A is the active center of endotoxin which exerts numer- 
ous biological activities both in vivo and in vitro [1,2]. The usual 
lipid A consists of a diglucosamine backbone with substitution 
of phosphate and fatty acid molecules. The relationship be- 
tween the chemical structure of lipid A and its endotoxic activ- 
ity has been studied by many investigators. A general concept 
of the relationship has been obtained, i.e. the preparations with 
the disaccharide backbone xhibit higher activity than those 
with the monosaccharide backbone, especially in toxicity. Both 
of the two phosphates in positions 1 and 4' play an important 
role in the manifestation of the full activity [3,4]. Fatty acids 
especially play an essential role in the activity. Their number, 
binding site and the kind appear to be critical determinants of
the capacity for the activity [5-7]. In fact, some of the non-toxic 
lipid A preparations so far found have the characteristic fatty 
acids with the usual diglucosamine backbone and phosphates 
[8-10]. Since the hydroxyl groups in lipid A act as the acceptors 
of the fatty acids, it seemed interesting to examine the role of 
free hydroxyl groups, or the substitution of the residues. 
The chemically synthesized isaccharide lipid A precursor 
406 (identical to lipid IVA or precursor Ia) has been shown, and 
was confirmed in this study, to be biologically active in mice 
[11,12]. It contains 4 free OH groups of 3-hydroxy myristic acid, 
some of which are substituted by fatty acids to form the com- 
plete lipid A (Fig. 1). In the previous tudy, I showed that the 
free hydroxyl groups in the complete lipid A preparations 
(E. coli and Salmonella types) are not required for the endotoxic 
activity [13]. I now show that, in contrast, the lipid A precursor 
406 lost all of its biological activity completely after substitution 
of free hydroxyl residues, and most importantly, these chemi- 
cally modified 406 preparations proved to be potent antago- 
nists of endotoxin in mice. I, hence, propose that the substitu- 
ents play a predominant role in both changing the endotoxically 
*Corresponding author. Fax: (81) (3) 3707 6950. 
active lipid A structure to an inactive form and into an antag- 
onist of endotoxin. 
2. Materials and methods 
2.1. Materials 
Synthetic lipid A analogues 406 was a gift of Daiichi Kagaku Co. Ltd. 
(Tokyo). Synthetic omplete lipid A (E. coli type; 506) was purchased 
from Daiichi Kagaku Co. Ltd. Lipopolysaccharide (LPS) was extracted 
from S. abortus equi by the aqueous phenol method [14]. Lipid A was 
obtained as an insoluble substance after treatment of LPS with 1% 
acetic acid at 100°C for 90 min [15]. Iscove's modified Dulbecco me- 
dium containing L-glutamine and HEPES (N-2-hydroxyeth- 
ylpiperazine-N'-2-ethanesulphonic acid) buffer and RPMI 1640 
medium were from GIBCO Laboratories (Grand Island, NY). Recom- 
binant TNFat standards and rabbit polyclonal antisera gainst murine 
TNF~ were obtained from Asahi Kasei Kogyo, Ltd. (Japan). 
2.2. Chemical modifications 
2.2.1. Succinylation of 406 and its chemical analysis [16,17]. A sus- 
pension of 5 mg of 406, 200 mg succinic anhydride, and 300/.tl of 
pyridine was heated in a sealed tube at 60°C for 3 h. Succinic acid 
introduced into 406 was liberated by hydrolysis with 4 M HCI for 3 h 
at 100°C and was determined by high-performance liquid chromato- 
graph (HPLC; Hitachi model L-6200) equipped with an ODS reverse- 
phase column (C18) (5 pm, 4 x 250 mm) containing Lichrosorb, using 
glutaric acid as the internal standard. 
2.2.2. Acetylation of 406. Five mg of 406 was dissolved in a solution 
of acetic acid anhydride and pyridine (0.2 ml each) in the presence of 
a small amount of dimethylaminopyridine. Th  mixture was allowed to 
stand overnight, hen dialyzed and lyophilized. 
2.3. Mass spectrometry 
Liquid secondary ion mass spectrometry (LSI/MS) was performed 
on a VG ZAB-2SEQ (VG Analytical, UK) operated at 8 kV in the 
negative mode. The caesium gun was operated at 30 kV. Current con- 
trolled scans were acquired at a rate of 30 s/decade. A mixture of 
ethanolamine and m-nitrobenzylalcohol (1:1) was used as the matrix. 
2.4. Assay of endotoxic activity 
2.4.1. Mitogenicity assay [18]. Spleen cells (8 x 105 cells/0.2 ml/ 
well) of serum-free Iscove's medium) obtained from 6--10-week-old 
female BALB/C, and C3H/HeJ mice were incubated with mitogen at 
37°C for 48 h. After a further 24 h incubation with [3H]thymidine (0.2 
/.tCi (7.4 kBq) per culture; Amersham), radioactivity incorporated into 
the cells was measured. The results are expressed as mean cpm of 
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Fig. 1. Structure of the chemically synthesized disaccharide lipid A (506), the precursor (406), and their succinylated and acetylated erivatives. 
Synthetic lipid A analogue 406 consists of 1,4'-bisphosphorylated glucosamine disaccharide substituted by 4 moles of R-3-hydroxy myristic acid at 
positions 2, 2', 3, and 3', and is identical to disaccharide lipid A precursor lipid IV A or precursor Ia. It lacks 2 acyloxyacylated fatty acids of 506 
(complete lipid A of E. coli), but is known to express adequate ndotoxic activity in animals. 
triplicate determinations. Standard errors were less than 10% in the 
mitogenicity assay and are not indicated in the figures. 
2.4.2. Inhibition of mitogenicity. The chemically modified prepara- 
tions, diluted reciprocally with pyrogen-free water, were added to the 
assay system together with mitogen in different ratios. The degree of 
reduction in [3H]thymidine incorporation was measured and compared 
with a control containing mitogen alone. Inhibition is expressed as the 
percent mitogenicity calculated thus; cpm of mitogen plus antagonist 
- cpm of background/cpm of mitogen - cpm of background. 
2.4.3. Induction of TNFot release from mouse peritoneal macro- 
phages. Mouse peritoneal macrophages (2 x l06 cells/ml of 
Iscove's medium) obtained from BALB/C mice (6-10-weeks-old) [19] 
were incubated with test sample at 37°C for 6 h with 5% CO2. The 
TNFct produced in the supernatant was determined by L929 cytotox- 
icity assay [13]. The results are expressed as means of triplicate determi- 
nations. 
2.4. 4. Lethal toxicity test. The lethality test was performed accord- 
ing to the method escribed by Galanos et al. [20], using female more 
than 10-week-old C57BL/6 mice obtained from Nihon SLC (Hama- 
matsu, Japan). Test samples in 0.1 ml of pyrogen-free water (Hikari 
Seiyaku Co. Ltd., Tokyo) were injected intravenously immediately after 
intraperitoneal administration f 12 mg of D-galactosamine (Sigma, St. 
Louis) in 0.5 ml of pyrogen-free PBS. 
3. Resu l t s  
3.1. Succinylation and acetylation of 406 
Mass spectrometry of 406 after succinylation and acetylation 
showed that five-to-six molecules of succinic residues were 
equivalently substituted for the 6 free hydroxyl groups of 406, 
while 6 acetyl residues were efficiently substituted in the precur- 
sor. No apparent degradation products, dephosphorylated or
deacylated forms, were observed in the spectra of either sample, 
indicating that no degradation, such as dephosphorylation r
deacylation, occurs during the course of chemical modification. 
The number of succinic residues introduced into 406 was esti- 
mated by measuring free succinic acid after hydrolysis of the 
sample with 4 N HCI using glutaric acid as the internal stand- 
ard. Succinylation resulted in the introduction of 5.6 mol of 
succinic residues into the lipid A precursor, providing quantita- 
tive confirmation of the results of mass spectrometry. 
3.2. Mitogenicity of  406 and its suecinylated and acetylated 
derivatives 
The mitogenic activity of lipid A precursor 406 and its suc- 
cinylated and acetylated derivatives was tested on murine 
splenic cells. As shown in Fig. 2, 406 exhibited greater mitogen- 
icity in the cells of endotoxin responsive BALB/C mice at both 
the minimum stimulation dose and the maximum stimulation 
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Fig. 2. Mitogenic responses of murine spleen cells to S. abortus equi 
LPS, 506, 406, and its derivatives. Murine spleen cels, 8 x 105 cells/well, 
were cultured with various concentrations of test samples for 48 h. 
Radioactivity ([3Hlthymidine) incorporated during an additional 24 h 
of culture was measured. The results are expressed as mean counts per 
minute in triplicate xperiments. The background counts per minute 
with no lipid A was 645 + 45 (mean + S.D.). Symbols: " ,  S. abortus equi 
LPS; G, 506; ©, 406; e, succinylated 406; z~, acetylated 406. 
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Fig. 3. Induction of TNF ~ release from routine peritoneal macroph- 
ages by LPS, 406 and its derivatives. Murine peritoneal macrophages, 
2 x 10 6 cells/ml, were cultured with various concentrations oftest sam- 
ples for 6 h and the supernatants were assayed for TNF0~. The results 
are expressed as means in triplicate xperiments. Symbols: I, S. abortus 
equi LPS; o, 406; o, succinylated 406; zx, acetylated 406. 
index than LPS from S. abortus equi or synthetic complete lipid 
A (E. coli type; 506). Activation occurred at even less than 
10 ng/ml, and the maximum cpm incorporated was 17,000, 
while S. abortus equi LPS or 506 stimulates cells at more than 
100 ng/ml, and the maximum radioactivity incorporated was 
12,000 cpm. The activity of 406 was completely lost both after 
succinylation and acetylation. No significant mitogenicity was 
detected with either succinylated or acetylated 406, even at 
100/lg/ml. Neither LPS nor 406 stimulated spleen cells from 
endotoxin non-responsive C3H/HeJ mice (data not 
shown). 
3.3. Induction of TNFo~ release by 406 and its succinylated and 
acetylated erivatives 
TNF~ released into the medium was estimated by cytotox- 
icity against actinomycin o-sensitized L929 murine fibroblasts. 
As shown in Fig. 3, murine peritoneal macrophages started to 
secrete TNF~ at a concentration f 1 ng/ml of 406. The produc- 
tion of TNF~ by macrophages increased ose-dependently, and 
maximum TNFct production, 22 ng/mi was observed at the 
highest concentration tested, 10/tg/ml. Its activity was a little 
less than that of S. abortus equi LPS, which stimulates ceils at 
0.1 ng/ml and induces 25 ng/ml of TNF~ at a concentration of
10/tg/ml. The activity of 406 was lost, however, by introducing 
succinyl or acetyl residues into the hydroxyl groups. No stimu- 
lation was observed even with 100/tg/ml of succinylated 406 or 
acetylated 406, indicating that its activity had been reduced 
more than 105-fold. 
No induction of TNFct release by either LPS or 406 was 
observed when peritoneal macrophages from C4H/HeJ mice 
were used. 
In order to confirm whether the cytotoxic activity against 
L929 ceils was due to TNFct, aliquots of the supernatants from 
macrophage culture were incubated for 12 h with polyclonal 
rabbit antiserum to TNF~ using non-specific IgG as the con- 
trol. The polyclonal antibody to TNF~ completely abolished 
the cytotoxicity of the supernatants stimulated with either LPS 
or 406. 
3.4. Lethality of 406 and its succinylated and acetylated 
derivatives 
The lethal toxicity of the samples was tested using galacto- 
samine-sensitized mice. The results are shown in Table 1. In this 
system, standard LPS from S. abortus equi and synthetic om- 
plete lipid A 506 exhibited 100% lethality at 10 ng/mouse and 
moderate l thality was observed at 1 ng/mouse. Lipid A precur- 
sor 406 was lethal at 10 ng/mouse, and at 100 ng/mouse it was 
100% lethal. On the other hand, lethality was expressed by 
neither succinylated nor acetylated 406, even at the maximum 
dose tested, 100/tg/mouse. 
3.5. Inhibition of endotoxic mitogenicity by succinylated and 
acetylated 406 
Since succinylated and acetylated 406 derivatives failed to 
activate mouse spleen cells, their inhibitory effects on the mito- 
genicity of S. abortus equi LPS were tested by adding them to 
spleen cell culture togehter with the mitogen. Fig. 4 shows the 
results of the antagonistic effects of succinylated and acetylated 
406 on the mitogenicity of LPS. Dose-dependent i hibition by 
succinylated 406 was observed over the 1-100/lg/ml range of 
LPS tested. Significant inhibitory effects were observed even at 
10-fold less succinylated 406 than LPS at all stimulation doses, 
and more than 90% inhibition was possible with 1-10-fold 
excesses of succinylated 406. The potency of inhibition of ace- 
tylated 406 was moderate and about 10 times less than that of 
succinylated 406 (Fig. 4). Similar inhibition was observed when 
LPS from E. coli or S. minnesota R595 (Re type) was used as 
the agonist. On the other hand, these chemically modified 406 
species did not inhibit the mitogenicity of concanavalin A even 
at 100/lg/ml. 
Table 1 
406 lost the lethal toxicity on galactosamine-sensitized mice after succinylation or acetylation 
Dose (pg/mouse) 
0.001 0.01 0.1 1 10 100 
Dead/total 
406 3/10 6/6 6/6 
Succinylated 406 0/3 0/6 0/3 
Acetylated 406 0/3 0/6 0/3 
LPS from S. abortus equi 3/8 6/6 
506 5/15 6/6 
The test samples in 0.1 ml of pyrogen-free water were injected intravenously, immediately after intraperitoneal administration f 12 mg of 
o-galactosamine  0.5 ml of pyrogen free phosphate-buffered saline. 
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Fig. 4. Inhibition of the splenocyte mitogenic activity of LPS by succinylated and acetylated 406. Reciprocally diluted antagonist in 10/21 of water 
was added to the splenocytes culture, followed immediately by the addition of 10/21 of various concentrations of S. abortus equi LPS and the 
mitogenicity was tested. Inhibition was expressed as the mean percent mitogenicity +S.D. of triplicate determinations, taking the incorporation of
radioactivity in response to the corresponding concentrations ofmitogen alone as 100% and background incorporation as 0%. Concentrations of 
LPS: e, 100/2g/ml; ©, 10/2g/ml; n, 1/2g/ml. 
4. Discussion 
Recently several nontoxic lipid A structures have been re- 
ported [8-10,21]. Such a non-toxic lipid A structure not only 
gives us more detailed information regarding the structure- 
activity relationship of lipid A, but also may be used as a potent 
inhibitor of the toxic action of endotoxin. Since antagonism 
against endotoxin action is generally observed with the sub- 
stances which chemically resemble the active lipid A but do not 
express endotoxicity [22-26], chemical modification of active 
lipid A is one of the most promising strategies for producing 
such non-toxic antagonists. My colleague and I found previ- 
ously that lipid A from S. abortus equi loses its mitogenicity for 
murine spleen cells by the introduction of succinic residues at 
the hydroxyl groups of lipid A and that the inactivated lipid A 
specifically antagonizes the mitogenicity ofendotoxin i  a dose- 
dependent manner [27]. The results uggest that some free hy- 
droxyl groups of lipid A are essential for its endotoxic activity 
and that substitution of the hydroxyl groups of lipid a is impor- 
tant for changing the endotoxically active lipid A structure to 
an inactive form and into an antagonist of endotoxin. To verify 
the hypothesis, I expanded my observations by using chemi- 
cally synthesized pure lipid A analogues. Among the analogues 
tested, complete lipid A preparations (E. coli and Salmonella 
type) were found, unexpectedly, to retain endotoxic activity 
fully after succinylation [13], indicating that the hydroxyl 
groups in these complete lipid A preparations are not required 
to exist in free form for endotoxic activity. In this study I have 
shown that, in contrast, the disaccharide precursor 406, a par- 
tial structure of complete lipid A, loses all of its biological 
activity upon chemical modification and changes to an antago- 
nist of endotoxin. Introduction of anionic and hydrophilic res- 
idues, such as succinic acid, may cause a drastic onformational 
change in lipid A in water, and hence may lead to the loss of 
endotoxic activity. Interestingly, however, introduction of non- 
anionic and hydrophobic acetyl residues into the hydroxyl 
groups also inactivated the endotoxicity of 406. And both the 
succinylated and acetylated 406 displayed inhibitory activity on 
endotoxic mitogenicity. These findings suggest that, regardless 
of the nature of the substituent, substitution of the hydroxyl 
groups of 406 is important in both changing the endotoxically 
active lipid A structure to an inactive form and to an antagonist 
of endotoxin, i.e. some of the free hydroxyl groups of 406 may 
be essential to the manifestation of its endotoxic activity. The 
difference in the chemical structure between the succinylated 
form of E. coli type lipid A and 406 is only the substitution of 
two hydroxyl residues of 3-hydroxy myristic acid of the non- 
reducing glucosamine (Fig. 1). This strongly suggests the im- 
portance of the substitution of the hydroxyl residues of these 
positions for the activity and for the transformation to the 
antagonistic structure. Considering that the hydroxyl residues 
of these positions are substituted by fatty acids in the complete 
and active lipid A preparations, the interpretation is not simple. 
The length of the substituent may also contribute to the activ- 
ity. Anyway, the dramatic loss of the endotoxic activity of 406 
after the substitution indicates that the substituents in these 
positions apparently modulate the endotoxic activity. 
In contrast o 406, neither succinylated nor acetylated 406 
exhibited any lethal toxicity when injected intravenously into 
mice even at the highest dose tested, 100/2g per mouse. For this 
reason, the present antagonists of endotoxin may be hopeful 
candidates of application to chemotherapy. 
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